Huajin Securities released a research report on April 13 stating that Maiwei Biotech (688062.SH) was given a purchase rating. The main reasons for the rating include: 1) Milesu's marketing contribution; 2) the commercialization of biosimilar drugs is progressing steadily, and emerging markets continue to be developed; 3) the research pipeline is progressing efficiently, and multiple indications of Nectin-4ADC shows positive curative effects; 4) It has a mature production transformation system and forward-looking layout of large-scale commercial production capacity. (Mainichi Keizai Shimbun)
华金证券4月13日发布研报称，给予迈威生物（688062.SH）买入评级。评级理由主要包括：1）迈利舒上市贡献新增量；2）生物类似药商业化稳步推进，新兴市场持续开拓；3）在研管线高效推进，Nectin-4ADC多适应症展现积极疗效；4）具备成熟生产转化体系，前瞻布局大规模商业化产能。（每日经济新闻）
Huajin Securities released a research report on April 13 stating that Maiwei Biotech (688062.SH) was given a purchase rating. The main reasons for the rating include: 1) Milesu's marketing contribution; 2) the commercialization of biosimilar drugs is prog
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.